Company description

APVO, or Aptevo Therapeutics Inc., is a biotechnology company focused on the development and commercialization of novel immunotherapies for the treatment of cancer and autoimmune diseases. The company was founded in 2016 as a spin-off from Emergent BioSolutions, and it is headquartered in Seattle, Washington. APVO's portfolio includes a diverse range of product candidates, including ADAPTIR™ bispecific antibody candidates, ADAPTIR-FNK fusion protein, and ADAPTIR-BCMA chimeric antigen receptor T-cell (CAR-T) therapy. These therapies stand out due to their unique binding capabilities and high specificity, which allow for targeted and potentially more effective treatment of diseases. Apart from its product pipeline, APVO also has a proprietary protein therapeutic platform, called ADAPTIR, which enables the production of versatile and high-quality protein-based therapeutics. This platform has been successfully applied to develop multiple product candidates, and it has the potential to generate significant revenue in the future. In addition to its innovative product pipeline, APVO has established strategic partnerships with leading pharmaceutical companies, such as Alligator Bioscience and Nektar Therapeutics, to further advance its research and development efforts. Despite being a relatively new company, APVO has made significant strides in the biotechnology industry, including obtaining FDA Fast Track designation for its lead candidate at one point. With a strong focus on cutting-edge science and strategic collaborations, APVO is well-positioned to continue making groundbreaking